128833-97-6 Usage
Description
3,5-Dichloro-DL-Phenylalanine is a chemical compound derived from the essential amino acid phenylalanine, featuring two chlorine atoms attached to its structure. This modification gives it unique properties that may be valuable in various applications, although it requires careful handling due to potential health hazards at high exposure levels.
Uses
Used in Pharmaceutical Industry:
3,5-Dichloro-DL-Phenylalanine serves as an intermediate or building block in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic targets, potentially leading to advancements in medicine.
Used in Research Applications:
In research settings, 3,5-Dichloro-DL-Phenylalanine is utilized as a tool to study the effects of chemical modifications on amino acid behavior and protein synthesis. This can contribute to a deeper understanding of biological processes and the development of targeted therapies.
Used in Chemical Synthesis:
3,5-Dichloro-DL-Phenylalanine is employed as a reactant in the synthesis of other organic compounds and specialty chemicals. Its distinct properties make it a valuable component in creating new materials with specific functions and applications across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 128833-97-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,8,8,3 and 3 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 128833-97:
(8*1)+(7*2)+(6*8)+(5*8)+(4*3)+(3*3)+(2*9)+(1*7)=156
156 % 10 = 6
So 128833-97-6 is a valid CAS Registry Number.
128833-97-6Relevant articles and documents
Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"
Varnavas, Antonio,Lassiani, Lucia,Valenta, Valentina,Mennuni, Laura,Makovec, Francesco,Hadjipavlou-Litina, Dimitra
, p. 563 - 581 (2007/10/03)
In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.
